Guidelines
FDA issues draft guidance on biosimilar meetings
The US Food and Drug Administration (FDA) has issued new draft guidance that provides recommendations to industry on formal meetings between FDA and sponsors or applicants relating to the development and review of biosimilar or interchangeable biological products.
FDA issues guidance on quality considerations for inhaled drugs
The US Food and Drug Administration (FDA) has issued draft guidance on quality considerations for inhaled drugs.
Global guidelines for biosimilars
Last update: 15 June 2018
The public health arm of the United Nations is World Health Organisation (WHO).
WHO, via its biological standardisation programme, develops guidelines and recommendations on the production and control of biological products and technologies.
FDA issues guidance on good manufacturing practice for APIs
The US Food and Drug Administration (FDA) has finalized revised guidance on good manufacturing practice (GMP) for active pharmaceutical ingredients (APIs).
FDA issues final guidance on bioanalytical method validation
On 21 May 2018, the US Food and Drug Administration issued final guidance on bioanalytical method validation.
TGA proposes changes to biologicals regulations
Australia’s drug regulatory agency, the Therapeutic Goods Administration (TGA) announced on 20 April 2018 the release of proposed amendments to its biologicals regulations that are set to take effect on 1 July 2018.
Regulation of biologicals in Colombia
Since the introduction of Decree 1782 Colombia has been moving towards a new regulatory landscape for biologicals (productos bioterapéuticos) and similar biotherapeutic products (productos bioterapéuticos similares) in the country [1].
EMA opens public consultation on GMP non-compliance template
The European Medicines Agency (EMA) announced on 3 April 2018 that it had opened a public consultation concerning the European Union (EU) template for good manufacturing practice (GMP) non-compliance statement.
FDA releases 52 new and revised bioequivalence guidelines for generic drugs
As part of its ongoing efforts to provide product-specific guidance for generics makers the US Food and Drug Administration (FDA) has again released several new and revised bioequivalence documents. The agency announced on 1 February 2018 that it had released 35 new draft guidance documents and 22 revisions to guidance documents on bioequivalence requirements for the development of generics containing 49 different active ingredients.
FDA issues guidance on co-crystals and impurities
The US Food and Drug Administration has finalized new guidance establishing co-crystals as a drug product intermediate. The agency has also released new information on when to submit elemental impurity data, acknowledging that new guidelines on reporting elemental impurities had slowed approvals in January 2018.
